Patient-Level DNA Damage and Repair Pathway Profiles Are Prognostic After Prostatectomy for High-Risk Prostate Cancer

      A substantial number of patients diagnosed with high-risk prostate cancer are at risk for metastatic progression after radical prostatectomy. However, the risk is not uniform, even among patients with clinicopathological treatment indications for adjuvant radiotherapy. Better biomarkers are needed to identify patients at highest risk so that therapy can be intensified, while sparing lower-risk patients from the side-effects of unnecessary therapy. We hypothesized that DNA damage and repair pathways (damage checkpoint, DNA repair, DSB repair, HRR, NHEJ, BER, NER, and MMR) could serve as prognostic biomarkers in high-risk prostate cancer.
      To read this article in full you will need to make a payment
      ASTRO Member Login
      ASTRO Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features.

      Purchase one-time access:

      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      Commenting Guidelines

      To submit a comment for a journal article, please use the space above and note the following:

      • We will review submitted comments as soon as possible, striving for within two business days.
      • This forum is intended for constructive dialogue. Comments that are commercial or promotional in nature, pertain to specific medical cases, are not relevant to the article for which they have been submitted, or are otherwise inappropriate will not be posted.
      • We require that commenters identify themselves with names and affiliations.
      • Comments must be in compliance with our Terms & Conditions.
      • Comments are not peer-reviewed.